Moderna's mRNA Flu Vaccine Receives FDA Advisory Panel's Approval

Moderna's mRNA flu vaccine has received strong backing from an FDA advisory panel, with option trading surging as a result. The approval is expected to have a significant impact on the company's stock price.

On June 18, 2026, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to recommend approval of Moderna's mRNA-based influenza vaccine, branded mFlusiva. The panel backed traditional approval for adults aged 50 to 64, and accelerated approval (contingent on follow-up confirmatory studies) for adults 65 and older. If the FDA follows the advisory committee recommendation, mFlusiva would become the first seasonal flu vaccine in the United States manufactured using mRNA technology.

The advisory panel vote is a significant regulatory milestone for Moderna MRNA, which had initially received an FDA rejection before regulators reversed course to reconsider the application. Unlike traditional egg-based flu vaccines, mFlusiva's mRNA platform allows faster reformulation to match circulating strains, potentially improving seasonal match rates and reducing production lead times. The FDA's formal approval decision is expected by August 5, 2026.

Options activity in Moderna surged sharply ahead of and following the vote, with contract volume reaching approximately 121,257 on the day. A related mRNA ETF also climbed roughly 60%, reflecting broader investor optimism that a positive MRNA flu decision could validate the platform's applicability beyond COVID vaccines. Moderna's stock has been highly sensitive to regulatory catalysts, and the advisory committee backing is likely to sustain near-term momentum, though the formal FDA decision in August remains the definitive gate.

Key risk factors for MRNA investors include the accelerated-approval pathway for the 65-and-older cohort, which imposes an obligation for additional confirmatory trials that could delay or limit that label expansion. Reimbursement negotiations and CDC immunization schedule inclusion will also determine commercial uptake, as flu vaccine adoption is heavily influenced by advisory committee recommendations and insurer coverage decisions. Analysts will watch the August FDA decision date closely, and any delay or label restriction relative to the VRBPAC recommendation could trigger a sell-the-news reaction.